ETHRIS
Planegg
About ETHRIS
ETHRIS develops mRNA therapeutics with a focus on respiratory diseases and vaccines. ETHRIS possesses an enabling LNP delivery and mRNA modification platform for transcript Therapies. SNIM®RNAis a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM®RNAs encode therapeutic proteins to be produced in the patient‘s body and overcome short duration effects of recombinant proteins. SNIM®RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, lifestyle- or age-related, rare or frequent.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: Less than $1M
- Total funding: $106.8M
- Last round: Grant (May 2025)
- Website: ethris.com
- Phone: +4908989557880
Industries & Categories
Bioinformatics, Biopharma, Biotechnology, Genetics, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ethris-35716 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.